Evidence map›Paper›PMID 41536679›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Clinicopathological Characteristics of Cervical Neuroendocrine Carcinoma and Their Relationship With Prognosis].

Ting Lan, Xiaohong Yao, Xiaoqing Zhou, Lin Shi, Jun Hou, Chengmin Zhou, Yang Liu, Min Shi

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting Lan，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.ORCID 0009-0004-4580-275X
Xiaohong Yao，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.
Xiaoqing Zhou，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.
Lin Shi，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.
Jun Hou，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.
Chengmin Zhou，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.
Yang Liu，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.
Min Shi，，，， （ 610041） Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Chengdu 610041, China.ORCID 0009-0000-4848-5164

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the clinicopathological characteristics and prognostic factors of cervical neuroendocrine carcinoma (NEC), and to clarify the independent prognostic value of the histological subtypes-mixed NEC (MiNEC) and pure NEC. Methods: A total of 45 cases of cervical NEC treated with radical surgery plus concurrent chemoradiotherapy at our institution between 2015 and 2024 were enrolled. Their clinicopathological features and prognosis were evaluated using immunohistochemistry, HPV RNAScope Results: The median patient age was 49 years (26-75 years) and the median follow-up was 24 months. The 1-, 3-, and 5-year OS rates were 75%, 61%, and 56%, respectively. According to the univariate analysis, FIGO stages Ⅲ and Ⅳ (hazards ratio [HR] = 3.78, 95% CI: 1.27-11.29, Conclusion: Under a treatment regimen of radical surgery combined with concurrent platinum-etoposide chemoradiotherapy, the FIGO stage is an independent prognostic factor for OS in cervical NEC. Due to the limited sample size, the association between histologic subtypes (MiNEC vs. pure-NEC) and long-term survival requires further validation with larger samples.

Indexed as

Carcinoma, NeuroendocrineUterine Cervical NeoplasmsAdultAgedChemoradiotherapyFemaleHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPrognosisCervical neoplasmsHPV RNAScopeMixed neuroendocrine carcinomaNeuroendocrine carcinomaSurvival analysis

Identifiers

PMID41536679
PMCPMC12796915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.